yankee2
2 years ago
CFMS .30 Nice news imo
Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the Company’s Actera™ Hip System.
Actera adds a tri-taper femoral stem design to the expanding Conformis hip portfolio. This advanced tri-taper design is becoming more common among orthopedic surgeons, as its design objective is to facilitate a minimally invasive approach similar to direct anterior, with easier access to the femur and consequently less injury to muscles and fewer potential interactions with nerves.
“We’re excited to expand Conformis’ hip portfolio with the addition of Actera, to satisfy the rise in surgeon demand for tri-taper stems,” said Mark Augusti, Chief Executive Officer and President of Conformis. “Surgeons have demonstrated a significant and growing preference for anterior total hip arthroplasty (THA) surgeries in recent years, and the innovative tri-taper stem is designed for easier placement. Peer-reviewed studies provide an increasing body of evidence that a tri-taper stem supports improved proximal load transfer and lower likelihood of implant loosening.”
Conformis will introduce the Actera hip system under a limited market release in select U.S. markets, which is expected to commence in the coming months. This complete THA system and supporting software has been developed to offer more personalized alternatives to cementless hip stems on market, while leveraging the Company’s advanced surgical planning and surgery in a box delivery model.
“The Actera hip, with its tri-tapered stem, is the natural evolution of the Conformis personalized portfolio,” said Dr. Robert T. Trousdale, M.D., a Board-certified orthopedic surgeon at the Mayo Clinic in Rochester, MN. “It is well-suited to whichever surgical approach is chosen by the surgeon.”
Chronology of the Conformis Hip Portfolio:
Conformis Actera™ Hip System: The Conformis Actera Hip System received FDA 510(k) marketing clearance in 2022. It utilizes an advanced tri-taper femur stem design that facilitates direct anterior approach total hip arthroplasties, and provides an additional stem option to orthopedic surgeons.
Conformis Cordera™ Hip System: The Conformis Cordera Hip System received FDA 510(k) marketing clearance in 2020. It is a cementless primary total hip replacement composed of femoral (thigh) and acetabular (socket of the hip bone) components. The system can be used with or without a pre-operative CT scan that is used to design Conformis iJigs® (patient-specific instruments) and a personalized surgical plan.
Conformis Hip System: The Conformis Hip System received FDA 510(k) marketing clearance in 2019. The Conformis Hip System is the only primary total hip replacement system on the market designed with 3D imaging technology to provide a stem and acetabular cup size that matches each patient’s specific ana
glta
yankee2
2 years ago
Good afternoon Who! CFMS .3685 adding on the way to dollars.Things are looking good ahead imo.Lets see what happens.
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta
yankee2
2 years ago
Hi Who! CFMS .287 Back in for another Ride North (:
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta
yankee2
2 years ago
Synchrony to Offer CareCredit Financial Services to Orthopedic Patients
March 22 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Conformis, Inc. (NASDAQ: CFMS), the pioneer and leader of fully personalized knee and hip replacement systems, today announced a strategic marketing partnership with Synchrony (NYSE: SYF) that will add the innovative Image-to-Implant® Platinum Services? Program to Synchrony’s successful CareCredit offering. The CareCredit credit card is accepted at more than 250,000 providers and health-focused retail locations, including 20 health systems, and has more than 11 million cardholder accounts.
CareCredit and Conformis will promote the availability of the CareCredit program to orthopedic surgeons and medical facilities across the United States. The strategic partnership is designed to provide an easy-to-use financing option for health facilities to offer to patients to help pay out-of-pocket costs related to knee replacement using Conformis systems, including personalization service upgrades under Conformis’ recently announced Platinum Services Program.
“Increasingly, patients undergoing orthopedic care, such as joint replacement, are choosing upgraded services that can result in out-of-pocket costs to the patient,” said Mark Augusti, Chief Executive Officer and President of Conformis. “We are excited about our marketing collaboration with Synchrony, which will allow medical facilities to offer CareCredit‘s convenient payment options to patients for these costs.”
The new marketing partnership will be highlighted during the 2022 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 22-26, 2022, in Chicago, IL at the Conformis Product Booth #1867 and at the CareCredit Booth #805.
When patients seeking orthopedic services have an out-of-pocket investment, cost can often be a concern and barrier to treatment. With the CareCredit credit card, orthopedic practices can help patients overcome this challenge and move forward with the recommended procedure and get the required implants or other therapeutic products they may need. CareCredit can also be used to pay for care not covered by insurance, including elective procedures, copays, deductibles and coinsurance.
“Providing financial solutions that can help increase access to healthcare services like orthopedics is imperative – especially in today’s economic environment,” said Claude Royster, Vice President, General Manager – CareCredit. “At CareCredit, we’re very pleased to join with Conformis in this effort because we share a common goal to do what we can to support the health and wellness of orthopedic patients, as well as the Doctors of Orthopedic Medicine and their practices.”
This partnership comes as more patients are interested in personalized medicine and have indicated a strong preference for fully personalized implants, as supported by a new clinical study published in The Journal of Bone & Joint Surgery Reviews (JBJS Reviews). The research found that bilateral knee patients prefer Conformis’ fully personalized solution over competitive off-the-shelf implants by a factor of more than 10 to 1.
Orthopedic practices accepting the CareCredit credit card who would like additional tools and resources to promote special financing should call 800.859.9975 or visit https://www.carecredit.com/providercenter/medical-specialties/. Practices not currently accepting CareCredit but who are interested in maximizing treatment acceptance should call 800.300.3046 or visit https://www.carecredit.com/providercenter/medical-specialties/ to learn more or enroll.
About Conformis, Inc.
Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services? Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future press releases via e-mail alerts, sign up at ir.conformis.com.
About CareCredit
CareCredit, a Synchrony solution, is a leading provider of promotional financing to consumers for health, veterinary and personal care procedures, services and products. For more than 30 years, CareCredit has helped millions of people by offering special financing options with convenient monthly payments.
About Synchrony
Synchrony (NYSE: SYF) is a premier consumer financial services company delivering customized financing programs across key industries including retail, health, auto, travel and home, along with award-winning consumer banking products. With more than $140 billion in sales financed and 80.3 million active accounts, Synchrony brings deep industry expertise, actionable data insights, innovative solutions and differentiated digital experiences to improve the success of every business we serve and the quality of each life we touch. More information can be found at www.synchrony.com and through Twitter: @Synchrony.
glta
Follow Board
Keyboard Shortcuts
Report TOS Violation
© Copyright 2022
About Us
Terms of Service
Privacy Policy
yankee2
2 years ago
CFMS .6734 Good morning Who there is some good stuff,alot of reading,looking now,they do have alot of cash, restructered debt
https://www.sfgate.com/business/article/ConforMIS-Q4-Earnings-Snapshot-16972423.php
Including results for cfms institutional buying.
Do you want results only for cfms intitutional buying?
Vanguard Institutional | Experienced Industry Experts
https://institutional.vanguard.com/vanguard/institutional
AdDiscover The Vanguard Difference: See How We Put Our Clients First. See How You Can Benefit From More Than 40 Years Of Asset Management Experience.
Bank of America - Investment Solutions
https://business.bofa.com/marketinsights
AdGet Trusted Advice and Execution Strategies to Help Achieve Your Strategic Goals.
Institutional Asset Management | and Investment Solutions
Adhttps://www.capitalgroup.com/institutional/investment
Conformis (NASDAQ:CFMS) Institutional Buying and Selling
Reporting Date
Hedge Fund
Shares Held
Market Value
Ownership in Company
2/23/2022 BlackRock Inc. 2,963,987 $2.26M 1.593%
2/16/2022 Wasatch Advisors Inc. 18,252,244 $13.90M 9.808%
2/15/2022 Stonepine Capital Management LLC 14,768,823 $11.25M 7.936%
2/15/2022 Millennium Management LLC 214,078 $0.16M 0.115%
24 more rows ...
Feb 24 2022
Phone: (844) 978-6257
Email: contact@marketbeat.com
Conformis Institutional Ownership and Major Shareholders ...
www.marketbeat.com/stocks/NASDAQ/CFMS/institutional-ownership/
Was this helpful?
People also ask
Where can I buy CFMS shares?
What happened to the CFMS IPO?
Will CFMS outperform or underperform the S&P 500 over the long term?
How much of conformis's stock is owned by institutions?
Feedback
Conformis Institutional Ownership and Major Shareholders ...
https://www.marketbeat.com/stocks/NASDAQ/CFMS/institutional-ownership
102 rows · Feb 23, 2022 · Of the 56 institutional investors that purchased Conformis stock in the last 24 months, the ...
Email: contact@marketbeat.com
Phone: (844) 978-6257
REPORTING DATE HEDGE FUND SHARES HELD MARKET VALUE
2/23/2022 BlackRock Inc. 2,963,987 $2.26M
2/16/2022 Wasatch Advisors Inc. 18,252,244 $13.90M
2/15/2022 Stonepine Capital Management LLC 14,768,823 $11.25M
2/15/2022 Millennium Management LLC 214,078 $0.16M
I am holding and adding on dips, I see this in the dollars in time.Lets see what happens today
Good luck and have a whopper of a day (:
glta
yankee2
3 years ago
CFMS .6742 Looking better imo
https://www.odtmag.com/contents/view_breaking-news/2022-03-02/conformis-suspends-product-delivery-to-russia/#:~:text=Conformis%20is%20suspending%20all%20distribution%20operations%20to%20Russia,distribution%20agreement%20for%20its%20devices%20in%20the%20country.
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta
yankee2
3 years ago
Good afternoon Who, i hear ya, everything beat down.this one has no excuse imo,no pr,s no updates.they need a new ceo imo.great company with piss poor management imo
i am holding.2nd time around,i cant see it going much lower.Who knows maybe they will let some news out,Covid does not help anything either.
glty
yankee2
3 years ago
CFMS I think We start heading north soon,so over sold imo
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
GL Who
glta
yankee2
3 years ago
CFMS .703 added a few more.
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta
mick
3 years ago
little cool but sleigh is packed
re;
CFMS .98 Now headed to the North Pole Happy Thanksgiving!
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta
yankee2
3 years ago
CFMS .98 Now headed to the North Pole Happy Thanksgiving!
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta
yankee2
3 years ago
CFMS $1.10 Rsi 31 I am adding, this is a bargain imo.
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta
yankee2
3 years ago
CFMS $1.30 I hope We are going to set a way-point due North.Added a few more at 1.21 I hope We stay above this price for good.
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta
yankee2
3 years ago
CFMS $1.33 RSI 40 w/ Double Bottom,Looking good imo
https://www.barchart.com/stocks/quotes/CFMS/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=CFMS&grid=1&height=500&studyheight=100
glta